Risk factors

New going concern doubts and heavy reliance on external financing dominate the risk profile.

Theravance Biopharma is heavily focused on the commercial performance and royalty streams of TRELEGY and YUPELRI.

Alora stopped non-DoD sales of DSUVIA and requested NDA withdrawal, threatening destruction of remaining inventory without DoD orders. Nasdaq issued a minimum bid price deficiency notice on March 11, 2026, threatening delisting.

Ultralife reorganized its brand portfolio, updated its tax carryforwards, and adjusted debt repayment figures following the Electrochem acquisition.

Xilio is developing masked immuno-oncology candidates, funded into 2027 with $137.5M cash plus recent equity and AbbVie milestone proceeds.

Aeva Technologies faces risks as an early-stage development company dependent on prototyping, customer adoption of 4D LiDAR, and third-party manufacturing.

Company is a blank check SPAC targeting the AI data center and cloud infrastructure industry. Risks focus on redemption rights, sponsor conflicts of interest, regulatory uncertainties under the Investment Company Act, and potential foreign operations.

Substantial doubt exists regarding the company's ability to continue as a going concern due to low cash and high working capital deficits. The company operates as a special purpose acquisition company seeking an initial business combination before December 31, 2027.

Bluerock Acquisition Corp. faces standard SPAC risks centered on finding a viable business combination target within the required timeframe.

Chain Bridge Bancorp updated figures, showing deposit growth to $1.6 billion and gross loans declining to $274.8 million.

Annual cash use increased from $5.3 million to $5.9 million, and operating loss grew from $5.7 million to $6.1 million. Cash and short-term treasuries increased to $7.2 million backed by over $40 million in cumulative offerings.

The company discontinued its parallel-import vehicle sales business to focus entirely on logistics and warehousing services.